Mechanisms of Reduced Vascular Tone Following Arteriogenesis Induced by Femoral Artery Ligation by Hatch, Christopher
MECHANISMS OF REDUCED VASCULAR TONE FOLLOWING ARTERIOGENESIS 
INDUCED BY FEMORAL ARTERY LIGATION 
 
 
 
 
 
 
A Senior Thesis 
Presented to 
the Faculty of California Polytechnic State University, San Luis Obispo 
 
 
In Partial Fulfillment  
of the Requirements for the Degree in 
Bachelor of Science in Biomedical Engineering 
 
 
 
 
 
By 
Christopher Justus Hatch 
August 2019 
 ii 
 
TITLE:  MECHANISMS OF REDUCED VASCULAR TONE 
FOLLOWING ARTERIOGENESIS INDUCED BY FEMORAL 
ARTERY LIGATION  
AUTHOR:   CHRISTOPHER JUSTUS HATCH 
DATE SUMBITTED:  AUGUST 2019 
ADVISOR:  TREVOR CARDINAL, ASSOCIATE PROFESSOR 
  
 iii 
ABSTRACT 
Mechanisms of Reduced Vascular Tone Following Arteriogenesis Induced by Femoral Artery 
Ligation 
 
Chris Hatch 
 
 The presence of a developed, native collateral network can decrease the severity of ischemic 
injury proceeding arterial occlusion. The collateral network must under arteriogenesis to enlarge 
and increase blood flow to the ischemic region. Although there has been tremendous effort 
attempting to understand the mechanisms of arteriogenesis, no therapies have been successful in 
improving patient outcome. To better understand the mechanisms involved in arteriogenesis, the 
effect of nitric oxide production, myogenic tone, and a-adrenergic receptors were evaluated as 
these have been identified as playing an important role in vascular injury. Arteriogenesis was 
induced by ligating the femoral artery between the epigastric and popliteal branches in male 
C57/BL6 mice between two to four months old. Pharmacological agents were dissolved in a 
physiological salt solution that was superfused over the exposed gracilis anterior to generate does 
response curves. The collateral diameter was measured using intravital microscopy. Diameter 
measurements were normalized to resting diameter to create percent changes for the operated 
vessels and contralateral sham. Procedures were performed at both seven and twenty-eight days 
following femoral artery ligation to evaluate how pathways changed with the restoration of 
vascular tone. Nitric oxide production does not appear to play an important role as the values for 
the day seven (-47 ± 7% for the operated and -43 ± 5% for the contralateral control) were similar 
to day twenty-eight (-31 ± 5% vs -27 ± 4 %, control and operated respectively). Myogenic tone 
does not appear to play an important role as the values for day seven (19 ± 3% for ligated and 31 
± 7% for the sham) are similar to day twenty-eight (25 ± 3% vs 39 ± 6%, ligated and sham 
respectively). a-adrenergic receptor stimulation appears to play an important role as there is a 
heightened response at day seven (-71 ±7 % vs -39 ± 6%, ligated vs sham respectively) 
compared to day twenty-eight ( -44 ± 4 % vs -31 ± 9%, ligated vs sham respectively). However, 
inhibition did not appear to be significant because there is a lack of response at both day seven 
(16 ± 9% vs 73 ±15 %, ligated vs sham, respectively) and day twenty-eight (16 ± 7% vs 50 ±7%, 
ligated vs sham, respectively). These findings suggest that there is lack of sympathetic 
innervation seven days after ligation that is restored twenty-eight days later.  
 
 
 
 
 
 
Keywords: arteriogenesis, a-adrenergic receptors, endothelial nitric oxide synthase, L-type 
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Introduction 
Peripheral artery disease (PAD) affects approximately 8.5 million people in the United 
States and manifests as intermittent claudication, or pain while walking [National, Di Minno, 
Criquie]. PAD is a type of ischemic disease caused by atherosclerosis of the lower extremities 
[Allen], and the most severe form of PAD is critical limb ischemia (CLI) which effects roughly 
11% of patients (figure 1) [Nehler]. CLI manifests itself as severe blockage in the arteries of the 
lower extremities that results in ischemic rest pain, gangrene, and ulcer formation [Samura]. 
Approximately 20-30% of the individuals with CLI cannot receive the common treatments of 
angioplasty or bypass due to comorbidities [Davies, Norgen]. As a result, about 20% of the CLI 
patient population faces mortality within five years [Norgen]. Therefore, there is a need for 
alternative therapeutic options to treat individuals with PAD or CLI that cannot receive the 
common treatments.  
 
 
Figure 1. Peripheral Artery Disease (PAD). PAD is the accumulation of plaque in the peripheral 
circulation, typically in the lower extremities [Peripheral]  
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  The presence of collaterals, or natural bypasses around the occluded region, can mitigate the 
severity of PAD [Annex] as increased collateral number is associated with improved functional 
performance [McDermott, Keeling].  Arteriogenesis, collateral growth, is a response mechanism 
to provide an ischemic region with sufficient blood flow by increasing the hemodynamic 
capability of the collaterals (figure 2) [Yu]. Many groups have tried to stimulate arteriogenesis in 
clinical trials by targeting the key processes involved. [Krishna, Annex, Raval, Maufus, Perin]. 
Arteriogenesis is caused by an increase in shear stress due to the occlusion that stimulates 
structural wall remodeling in an attempt to normalize shear stress [Troidl, Mack]. Additionally, 
the occluded vessel can create a hypoxic region downstream that leads to cells releasing pro-
angiogenic cytokines and growth factors [Landázuri, Annex]. These growth factors and 
increased shear stress mobilize progenitor and inflammatory cells from the bone marrow to enter 
the surrounding tissue and start the process of arteriogenesis [Landázuri, Mack]. Numerous cells 
and pathways have been targeted to develop therapeutic treatments stimulating arteriogenesis 
[Krishna, Annex, Raval, Maufus, Perin]. The pro-angiogenic vascular endothelial growth factor 
(VEGF) was regarded as one of the most likely candidates for treatment. VEGF induces 
monocyte chemoattractant protein -1 (MCP-1) in endothelial cells (ECs) which leads to 
monocyte recruitment, and it stimulates EC proliferation and migration [Jazwa, Schaper]. Other 
approaches focused on colony stimulating factor, progenitor cells, and autologous bone marrow 
derived mononuclear cells [Raval, Maufus, Perin]. Although there were promising results in 
preclinical models, there has been no conclusive efficacy in larger human randomized clinical 
trials [Krishna, Annex, Raval, Maufus, Perin]. 
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Figure 2. Mechanisms of Arteriogenesis. Increased shear stress leads to monocyte recruitment that stimulates 
arteriogenesis [Schirmer] 
 
 Therefore, it might not be sufficient for these collaterals to reperfuse downstream tissue 
by acting solely as larger conductance pathways because abnormal vascular reactivity might 
limit the therapeutic effects of collaterals [Bauters]. Collaterals should also be able to regulate 
blood flow to match oxygen delivery with tissue metabolic demand [Rey]. Normally, blood flow 
is locally controlled to ensure sufficient oxygen to tissues. However, following ischemia, blood 
flow is controlled by a high resistance collateral circuit that must have a functional range that can 
accommodate varying levels of tissue metabolic demand [Taylor]. Therefore, it is interesting that 
most investigators focus on maximum diameter measurements, which does not provide 
information about the resting diameter and vascular reactivity, which define the ability of a 
resistance vessel to regulate blood flow. [Gruionu, Heuslein, Clayton]. In order to develop new 
therapeutic strategies, a greater understanding of the processes of vessel adaption is needed, 
which can be accomplished by evaluating vascular reactivity [Jaipersad]. 
 Although clinical observations in patients with PAD show a loss of vascular reactivity, there 
is no consensus on the underlying mechanisms [Silva, Langham]. One explanation is endothelial 
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dysfunction, as patients with PAD have greater endothelial dysfunction with impaired 
vasodilation [Parshakov]. However, patients with PAD have significantly higher plasma NO 
levels compared to non-PAD patients [Miralles], suggesting that the lack of vasodilation is 
caused by insensitivity of SMCs to NO [Silva]. SMCs display both contractile and synthetic 
phenotypes, each with diverse migration rates and protein expression [Rensen], and SMCs 
switch between the two phenotypes based on environmental stimuli [Gomez]. A pro-
inflammatory environment causes SMCs to transition into a synthetic, largely noncontractile 
phenotype [Brozovich]. During arteriogenesis, there is an increase in regulator of G-protein 
signaling 5 (RGS5), which terminates signaling cascades that control contractility of SMCs 
[Arnold]. Both factors could affect the ability of SMCs to regulate vascular reactivity, which 
would lead to reduced functionality. In newly formed collaterals of the mouse spinotrapezious 
muscle, there is a loss of vascular reactivity via impaired vasodilation and lack of 
vasoconstriction seven days after arteriogenesis begins, which is caused by a lack of SMCs 
contractility. However, these are presumably new SMCs in the region, which might explain the 
restoration of vascular reactivity at twenty-one days [Gouin III]. The lack of agreement on the 
cause of a loss of vascular reactivity in PAD patients suggests the need to further examine the 
basic mechanisms driving collateral remolding . If important signaling pathways can be 
identified, better therapeutics might be developed [Heuslein, Jaipersad]. 
 Vascular tone is regulated by vasoconstriction and vasodilation of the collaterals that include 
many signaling pathways (figure 3) [Korthuis, Tykocki, Durand, Dora]. Myogenic tone, the 
mechanism responsible for pressure-dependent, steady state contractility of SMCs, plays a 
prominent role in regulating vascular tone [Jackson]. Specifically, L-type voltage Ca2+ channels 
(LVCCs) are integral as they are major source of activator Ca2+ in myogenic tone [Tykochi]. 
Fluid shear stress regulates vascular tone by activating endothelial nitric oxide synthase (eNOS) 
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that creates NO [Iring]. NO then acts as a vasodilator of SMCs, thus regulating vascular tone 
[Zhao Vascular nitric oxide]. Release of norepinephrine (NE) from sympathetic nerves targets a-
adrenoreceptors thus helping to regulate vasoconstriction [Calzada]. In a1-adrenoreceptors, NE 
increases the inositol triphosphate (IP3) pathway which leads to an increase in intercellular Ca2+ 
and SMC vasoconstriction. On the other hand, in a2-adrenoreceptors, NE inhibits the adenylyl 
cyclase (cAMP) pathway leading to vasoconstriction. Although there are other pathways, in 
peripheral vascular disease these have been identified as being the most important [Frisbee].   
 
Figure 3. Regulation of Vascular Tone. L-type Ca2+ channels increase SMC intercellular Ca2+ leading to increased 
vasoconstriction. NE stimulates vasoconstriction. NO produced from shear stress leads to vasodilation 
 
 Previous work in the lab has demonstrated that arteriogenesis following femoral artery 
ligation induces a loss of vascular tone that is restored at a later point in time [Chu]. The goal of 
this work was to evaluate the signaling pathways that might be responsible for the loss.  
 
 6 
Methods 
Animals: All procedures were performed according to a protocol approved by the 
California Polytechnic State University Institutional Animal Care and Use Committee. Male 
C57BL/6 mice (The Jackson Laboratory; Sacramento, CA) between two and four months were 
used for all experiments. The mice were maintained on a twelve-hour light/dark cycle with ad 
libetum access to food and water. Mice were housed in microisolator cages and provided nesting 
material, plastic tube, and “housing”.  
Femoral Artery Ligation: Chronic hindlimb ischemia was induced by ligating the femoral 
artery between the epigastric and popliteal branches [Limbourg]. Animals were anesthetized in 
an induction chamber with 5% isoflurane in oxygen flowing at 1L/min. Hair was removed using 
depilated cream and skin was disinfected with chlorhexidine diacetate. Ophthalmic ointment was 
applied to prevent corneal desiccation. Pre- and post-surgical buprenorphine analgesic (0.075 
mg·kg-1) was administered and body temperature was maintained at 35°C through the use of a 
temperature-controlled heat pad and rectal thermistor probe (CWE, Inc.; Ardmore, PA). 
Following a skin incision above the neurovascular bundle in the hindlimb, the left femoral artery 
was separated from the neurovascular bundle distal to the epigastric branch and proximal to the 
deep femoral branch. The femoral artery was ligated with 6-0 silk suture. The incision site was 
then closed with 7-0 polypropylene suture. A sham surgery was performed on the contralateral 
hindlimb, in which the skin was exposed and the connective tissue overlying the femoral 
neurovascular bundle was blunt dissected before skin closure. Mice recovered on a heat pad until 
ambulatory.  
Solution Preparation: The physiological salt solution (PSS, ~35oC, pH~7.4) was 
composed of (in µM): NaCl 137, KCl 4.7, MgSO4 1.2, CaCl2 2, and NaHCO3 18. Nitric oxide 
synthase inhibitor Nw-Nitro-L-arginine methyl ester hydrochloride (L-NAME, Sigma-Aldrich, 
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Lot No: MKBV9596V) and norepinephrine (NE, Sigma-Aldrich, Lot No: BCBR1921V) were 
dissolved at 10-3 M and stored at -20°C until the day of the procedure. Norepinephrine receptor 
inhibitor (α1) prazosin (Cayman Chemical, Lot No: 0446327-23), (a2) rauwolscine (Cayman 
Chemical), and calcium channel blocker nifedipine (Cayman Chemical) were dissolved at 10-3 M 
and freshly prepared. 
Superfusion: 7 or 28 days following femoral artery ligation, animals were prepared as 
previously described. The gracilis muscle was exposed via skin incision and connective tissue 
was removed. A trans-illuminating LED probe was placed under the hindlimb to allow 
visualization of the primary collateral. 60 ml of PSS was placed in a syringe heater (custom 
built) and deoxygenated with 5% CO2 - 95%N2. PSS was then passed over the exposed collateral 
at ~35°C at ~2 ml/min for an equilibration period of at least thirty minutes. Resting images were 
captured using an intravital microscope (Olympus BXFM) with a 10X objective (Olympus 
LMPlanFL N) and a digital imaging software (QCapture Pro). Responses to pharmacological 
agents were determined from 10-8 M to 10-4 M over a period of five minutes. The procedure was 
repeated on the sham side; if necessary, the entire process was then repeated for additional 
agents.  
Perfusion Fixation: 7 or 28 days post-ligation, perfusion fixation was used to preserve 
gracilis tissues. Before perfusion, gracilis anterior muscles were separated from surrounding 
fascia to facilitate resection. After exposing the thoracic cavity, a 27G catheter was inserted into 
the left ventricle via the apex of the heart, and the right atrium was cut to create an open system.  
A 60 ml syringe loaded with a warm solution of 40 ml PBS containing 10-3 M Sodium 
Nitroprusside, 10-4 M Adenosine, and 100 U/ml Heparin as an anticoagulant was perfused at 
4ml·min-1 using a 10 ml syringe. Afterwards, animals were fixed with 5 ml of cold 4% 
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paraformaldehyde. Once fixed, gracilis anterior muscles were resected from the profunda 
femoris artery to the distal saphenous artery.  
 Immunofluorescent: Gracilis anterior muscles were whole-mount immunostained to visualize 
vasculature (a-smooth muscle actin) and sympathetic innervation (tyrosine hydroxylase). 
Following resection, muscles were incubated in 2% Triton-X-100 in 1X PBS for 2 hours at room 
temperature. Muscles were then stained with 0.1% Triton-X-100, 2% BSA, 1:300 Anti-Actin a-
smooth muscle – Cy3 antibody mouse monoclonal (Sigma-Aldrich C6198), 1:1000 Anti-
Tyrosine Hydroxylase Antibody (Millipore Sigma AB152) in PBS at 4°C for 96 hours. They 
were then washed in PBS three times for 10 minutes at room temperature. Muscle were 
incubated with 1:100 of secondary Goat anti-Rabbit IgG Cross-Adsorbed Secondary Antibody, 
Alexa Flour 488 (ThermoFisher A11008) for 24 hours at room temperature and washed in 0.1% 
Triton-X-100 in PBS three times for 10 minutes at room temperature followed by a 30 minute 
wash in PBS at room temperature. Muscles were mounted on depression slides with 50/50 
glycerol (Sigma G7757-1L) and PBS and stored in 4°C for one day before imaging. 
 Imagining: Whole muscles were imaged at 10X and 20X on an Olympus FV1000 confocal 
microscope using the Alexa Fluor 488 and Texas red dye (594 nm) filter settings. Images were 
captured using the Multi-Area Time-Lapse feature by identifying the region of interest using the 
mosaic outline.  
Measurements and Statistics: Vessel diameters were measured with Image/J software at 
three different regions in the primary collateral. Differences between all concentrations and sham 
and ligated sides were tested using repeated measured ANOVA followed by Tukey pairwise 
comparisons. Percent change was calculated as the difference between a given time point and 
resting diameter divided by resting diameter. All measurements are displayed as mean ± standard 
error.  
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Results: 
  The goal of this work was to identify signaling pathways that contribute to the restoration of 
vascular tone following arteriogenesis. The three pathways that were evaluated were nitric oxide 
production, myogenic tone, and a-adrenoreceptors because they have been identified as being 
the most important in peripheral vascular disease [Frisbee]. 
 The first pathway that was evaluated was NO production by inhibition with LNAME. Seven 
days post femoral artery ligation the resting diameter on the ligated side was 83 ± 9µm with a 
minimum diameter of 51 ± 5µm (Figure 4C). The contralateral sham had a resting diameter of 44 
± 3µm with a minimum diameter of 30 ± 2 µm (Figure 4C). In order to gain greater clarity, 
values were converted to percent change. The percent change normalized measurement to the 
resting diameter, eliminating any bias from varying resting measurements.  This translated to a 
functional range of -47 ± 7% for the operated and -43 ± 5% for the contralateral control (Figure 
4E). Twenty eight days later both the contralateral control and operated had similar percent 
changes, -31 ± 5% vs -27 ± 4 %, respectively (Figure 4F). The operated side has a resting 
diameter of 44 ± 3µm and a minimum diameter of 30 ± 2µm; whereas, the contralateral control 
has a resting diameter of 33 ± 2µm and a minimum diameter of 24 ± 2µm (Figure 4D). Because 
there is no statistical significance between the percent change at day seven and day twenty eight, 
it is likely that NO production is not responsible for the loss of vascular tone and later 
restoration.  
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Figure 4. The effect of nitric oxide on collateral growth. NO does not appear to play a significant role in restoring 
vascular reactivity. The representative images of the resting (A) and 10-4 M (B). There appears to be no significant 
difference in vascular reactivity at either 7 days (C,E) or 28 days (D,F) post-femoral artery ligation. The difference 
observed in the micron measurements is caused by an increased resting diameter on the ligated side * = p<0.05 
between ligated and sham. % = p<0.05 between ligated day seven and day twenty-eight. 
 
Because an excess vasodilating influence does not appear to be responsible, another 
possibility was an insufficient vasoconstricting influence. Therefore, the second pathway that 
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was evaluated was myogenic tone. Specifically, L-type voltage gated calcium channels (LVCCs) 
were inhibited with nifedipine. tone. If myogenic tone played an important role, it would be 
expected that there is a reduced influence of inhibition at day seven compared to day twenty 
eight. Seven days following ligation the resting diameter of the ligated side was 86 ± 3µm with a 
max diameter of 102 ± 2 µm. The sham side had resting diameter of 41 ± 3µm and a max 
diameter of 53 ± 4µm (Figure 5C). This corresponds to a 19 ± 3% functional range for the 
ligated side compared to a 31 ± 7% range for the sham (Figure 5E). Twenty eight days later, the 
functional range for the ligated side remained relatively unchanged with a resting diameter of 70 
± 6µm and a max diameter of 88 ± 7µm. The sham has a resting diameter of 39 ± 6µm and a 
max diameter of 53 ± 6µm (Figure 5D). This produces a functional range of 25 ± 3% for the 
ligated side compared to 39 ± 6% for the sham (Figure 5F). Because there is only one 
concentration between both time points that is statistically different between the ligated and 
sham, it is likely that the loss and restoration of vascular tone is not caused by LVCCs and 
myogenic tone. Therefore, the hypothesis that myogenic tone plays a vital role is rejected 
because there was not a reduced impact at day seven. 
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Figure 5. Effect of myogenic tone on collateral growth. Myogenic tone does not appear to play an important role 
in regulating vascular tone following arteriogenesis. The representative images at day seven between resting (A) and 
10-4 M (B). There appears to be no significant difference in vascular reactivity at either 7 days (C,E) or 28 days (D, 
F) post-femoral artery ligation. The difference observed in the micron measurements is caused by an increased 
resting diameter on the ligated side. * = p<0.05 between ligated and sham. % = p<0.05 between ligated day seven 
and day twenty-eight. 
 
 The third pathway that was evaluated was a-adrenergic receptors. In order to support a 
hypothesis that VSMCs were in a state of proliferation, a minimal response to stimulation of a-
adrenergic receptors at day seven and increased response at day twenty-eight would be expected. 
To test this, the receptors were stimulated with NE. At seven days post femoral artery ligation, 
the collaterals on the operated side had a resting diameter of 78 ± 8µm and a minimum diameter 
of 28 ± 5µm, while the contralateral control had a resting diameter of 48 ± 3µm with a minimum 
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diameter of 30 ± 3µm (Figure 6C). The functional range of the operated side was -71 ± 7% 
compared to -39 ± 6% for the sham, suggesting that VSMCs were hypersensitive to stimulation 
(Figure 6E). However, at day twenty eight, vasoconstriction caused by NE was not statistically 
different between the operated side and contralateral control, -44 ± 4 % vs -31 ± 9%, respectively 
(Figure 6F). The resting diameter for the operated side at day twenty-eight was 46  ± 3µm and 
the minimum diameter was 26 ± 2µm. The resting diameter for the contralateral sham was 33 ± 
3µm with a minimum diameter of 23 ± 3µm (Figure 6D). This would suggest that VSMCs 
phenotype is not responsible for the loss and restoration or vascular tone. Interestingly, it appears 
that a-adrenergic receptors are hypersensitive to stimulation suggesting that there might be 
insufficient NE signaling. 
To evaluate the presence of a-adrenergic stimulation, prazosin, an a1-adrenergic 
antagonist was applied to induce vasodilation. At day seven, prazosin reduced vascular tone in 
the contralateral control significantly more than in the enlarged collateral, increasing diameter 73 
±15 % vs 16 ± 9%, respectively (Figure 6I). The resting diameters for the resting of contralateral 
sham and operated were 25 ± 2 µm and 47 ± 10µm, respectively. The maximum diameters were 
44 ± 8µm and 53 ± 7µm, control vs operated, respectively (Figure 6G). This trend was consistent 
at day 28 where the vasodilation between the operated and contralateral was significantly 
different, 16 ± 7% vs 50 ±7%, respectively (Figure 6J). The resting diameter and max diameter 
for the contralateral control were 28 ± 3µm and 42 ± 4µm, respectively. For the operated, the 
resting diameter was 40 ± 3µm and the max diameter was 47 ± 6µm (Figure 6H).   
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Figure 6. The role of a-adrenergic receptors in collateral growth. Stimulation, but not inhibition, of a-
adrenergic receptors appear to play a role in the restoration of vascular tone at day twenty-eight. Collaterals 
demonstrate regional reactivity to a-adrenergic agonists at 7 days post femoral artery ligation as shown by the 
difference between resting (A) and stimulation with 10-4 M NE (B). Collaterals appear to be hypersensitive to a-
adrenergic agonists at 7 days (C,E), but not 28 post femoral artery ligation (D,F). a-adrenergic antagonists appear to 
be similar to contralateral sham at both time points (G-J).  The difference observed in the micron measurements is 
caused by an increased resting diameter on the ligated side. * = p<0.05 between ligated and sham. % = p<0.05 
between ligated day seven and day twenty-eight. 
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Figure 7. Role of Sympathetic Innervation in Arteriogenesis. Sympathetic innervation should play an important 
role in arteriogenesis. a-smooth muscle actin (red) and tyrosine hydroxylase (red). There is significant background 
noise/autofluorescence from the tissue. The entire gracilis anterior of unligated Balb/C at 10X magnification (A). 
Midzone of gracilis anterior at 20X (B). Midzone at 20X with fewer z stacks of tyrosine hydroxylase to enable 
viewing of innervation (C). Innervation is solid green surrounding collateral  
 
 
Discussion  
 Femoral artery ligation is a viable model to study the loss and restoration of vascular tone 
[Chu]. Seven days post femoral artery ligation there is an increased resting diameter and a 
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decreased functional range that is restored at twenty-eight days [Chu]. It was hypothesized that 
either nitric oxide (NO) production, myogenic tone, or a-adrenoreceptors were responsible for 
causing this because these mechanisms were identified as being the most important in peripheral 
vascular disease [Frisbee]. However, an increase in NO production is not a factor (Figure 4) as 
inhibition of NO via LNAME had similar effects on both the sham and operated at both day 
seven and day twenty-eight. Also, myogenic tone is not responsible for the restoration of 
vascular tone (Figure 5) as there were no statistically significant trends in the percent change for 
sham and operated at both time points. a-adrenoreceptors appear to play an important role in 
regulating vascular tone following femoral artery ligation (Figure 6). At day seven, but not day 
twenty-eight, there is increased sensitivity to stimulation of a-adrenoreceptors with NE (Figure 
6).  
It is unlikely that excess NO production from increased shear stress plays an important 
role in the loss of vascular reactivity following collateral growth. There has been conflicting 
results on the role of endothelial nitric oxide synthase and arteriogenesis. Systemic inhibition of 
NO by treatment with LNAME from three to twenty-eight days after femoral artery resection led 
to a decreased recruitment of vascular progenitor cells, specifically hemangiocytes 
[Park/Hoffman]. Furthermore, this led to a decreased collateral diameter compared to mice 
without inhibition, leading to the conclusion that NO is important in regulating arteriogenesis 
during the first month following an ischemic event. [Park/Hoffman]. However, eNOS is 
necessary for vasodilation immediately after femoral artery ligation, but not for collateral growth 
[Mees]. In eNOS knockout mice blood flow is only decreased compared to wild type until day 7, 
where afterwards they become similar [Mees]. Furthermore, a possible explanation for the 
disagreement in literature is that more invasive and damaging methods, such as resection, might 
induce both arteriogenesis and angiogenesis and thus might provide information that is not 
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unique to arteriogenesis [Mees]. All of this would suggest that another pathway should play a 
more prominent role.  
 Myogenic tone plays an important role in determining resting vascular tone in healthy 
individuals [Howitt], and it has been hypothesized that SMCs phenotype switching relies on 
suppression of L-type voltage gated calcium channels (LVCCs) [Wamhoff]. In a rat aortic 
balloon injury, at day two and seven SMC proliferation increased and LVCCs were reduced 
[Quignard]. However, LVCCs were restored by day thirty [Quignard]. This is not consistent with 
the femoral artery ligation, as there appears to be no downregulation in LVCCs at either time 
points (Figure 2). Interestingly, seven days post femoral artery ligation SMC proliferation peaks 
(Bynum, unpublished). Therefore, it would be expected to see a loss of LVCCs influence at day 
seven. A possible explanation is that an aortic balloon injury causes more damage than a femoral 
artery ligation. This increased damage might correspond to greater SMC proliferation and thus 
greater downregulation of LVCCs. However, a more likely explanation is that another pathway 
plays a more prominent role. In other models, NO deficiency leads to T-type calcium channels 
become more important in regulating vascular tone as shown by the ability to increase vessel 
diameter greater than inhibition with LVCCs [Howitt]. Although it is unlikely there is NO 
deficiency in arteriogenesis, this raises the possibility that other pathways that regulate myogenic 
tone might become more important in regulating vascular reactivity. Transient receptor potential 
cation channel subfamily V member 4 (TRPv4) activation enhances arteriogenesis, suggesting 
that it might play a more prominent role in regulating vascular tone [Troidl, Schierling]. Inositol-
1,4,5-triphosphate receptors (IP3R) and ryanodine receptors (RyR) regulate intracellular Ca2+ 
concentration. During SMC proliferation there is a reduction in RyR, but not IP3R [Vallot]. 
After SMC differentiation, the number of RyR matches those found before proliferation [Vallot]. 
Evaluation of RyR receptors following arteriogenesis might provide insight into the role of 
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myogenic tone in regulating vascular tone; however, it is challenging to find pharmacological 
agents that selectively target these pathways in vivo [Tykocki].  
 Inhibition of a-adrenergic receptors is probably not responsible for the loss of vascular tone. 
When only a-1-adrenegic receptors are inhibited following femoral artery occlusion there is no 
change in the conductance of the collateral circuit [Taylor]. However, catecholamine synthesis 
appears to play an important role in collateral vessel growth. When catecholamine synthesis is 
knocked out via gene deletion of dopamine b-hydroxylase, there is reduced collateral vessel 
growth [Chalothorn]. Furthermore, denervation upstream of the gracilis anterior before ligation 
leads to impaired arteriogenesis as demonstrated by a decreased collateral diameter [Cen]. On the 
other hand, stimulation of a-adrenergic receptors leads to increased SMC proliferation following 
aorta balloon injury [Erami]. Although there was no change between inhibition of a-adrenergic 
receptors at day seven and day twenty eight, there was an increased response to a-adrenergic 
stimulation at day seven, but not at day twenty-eight that would imply stimulation of a-
adrenergic might be responsible for the restoration of vascular tone. Interestingly, this trend is 
evident in patients with CLI, as there is increased vasoconstriction in ischemic skeletal muscle 
compared to non-ischemic [Jarajapu]. Furthermore, a three hour acute ischemic condition in 
canine femoral arteries showed not only increased contractility towards norepinephrine, but also 
a decrease in prazosin and Rauwolscine induced vasodilation [Sapienza]. The increase in 
vasoreactivity was caused by increased density and functional activity of a-adrenergic receptors 
[Sapienza]. Therefore, it is possible that there is an increase in functional activity and density of 
a-adrenergic receptors at day seven leading to increased hypersensitivity that is restored at day 
twenty eight.  
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 On another note, the hypersensitivity of NE and reduced a-adrenergic receptor activity at day 
seven could be symptomatic of a lack of sympathetic innervation. In rat soleus muscles there is 
an increase in chemosensitivity following resection of the sciatic nerve in the thigh [Jones]. This 
suggests that the hypersensitivity of NE at day seven could be caused by lack of innervation. 
During arteriogenesis, MMPs degrade the tissue structure [Cai 2000]. We hypothesize that 
during this remodeling the sympathetic innervation is either damaged or distances itself from the 
collaterals.  Following nerve crush, blood vessel diameter increases until nerve regeneration 
leads to a greater regulation of vascular tone [Podhajsky].  Further support of this concept comes 
from angiogenesis where vascularization precedes innervation As time proceeds, MMPs are 
downregulated [Cai 2000], which could allow the sympathetic nerves to fully innervate 
collaterals leading to greater regulation of vascular tone. Therefore, the restoration of vascular 
tone that is seen at day twenty-eight likely correlates with an increase in vascular tone. A 
possible way to evaluate this is to stain for sympathetic innervation and a-smooth muscle actin at 
both day seven and day twenty-eight. In Balb/C mice, anti-tyrosine hydroxylase was used to 
stain for sympathetic innervation (Figure 7). Some optimization is necessary before this stain can 
be implemented. Furthermore, changing the secondary to a different wavelength, such as 647 
nm, might remove the background noise from the tissue.  
Interestingly, treatment with nerve growth factor (NGF) improves arteriogenesis by 
increasing arteriole density [Emanueli]. In spite of this, there appears to be a lack of interest in 
sympathetic innervation in clinical trials, possibly because there is no significant difference 
between biomarker expression of NGF in healthy individuals compared to individuals with PAD 
[Gardner]. Future studies could evaluate the role of Netrin-1 and arteriogenesis. Netrin-1 is an 
axon guidance cue produced by SMCs that regulates arterial innervation, and a lack of Netrin-1 
leads to defective vasoconstriction [Brunet]. Future studies could determine how Netrin-1 
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expression changes during SMC phenotype switching to see if it might play a role in re-
innervation of sympathetic neurons.  
 Ultimately, stimulation of arteriogenesis has the potential to be a therapeutic treatment for 
PAD. Although there has been success in preclinical models, no treatment has had clinical 
success, which points to the need for a greater understanding of the underlying mechanisms. 
Evaluation of vascular reactivity has the potential to provide insight into novel therapeutic 
options. There is a larger resting diameter and increased sensitivity to NE seven days post 
femoral artery ligation, but by twenty-eight days post femoral artery ligation the resting diameter 
has decreased and NE sensitivity is on par with the contralateral sham. This suggests that there is 
a loss of sympathetic innervation at day seven that is restored at day twenty-eight. Therefore, 
future therapeutics should target sympathetic innervation to improve patient outcome.  
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Appendices: Protocols 
 
Date ______________    Hindlimb Ischemia Surgery – Femoral Artery Ligation Initials ___________ 
 
Mouse Information 
Age: _____________________  
Sex: _____________________   
Tag: _____________________  
Genotype/strain: ____________  
Cage: ____________________  
 
Purpose: ___________________________________ 
___________________________________________ 
 
Materials 
Pre-sterilize in autoclave 
____1. Standard pattern forceps (1) 
____2. Fine forceps- S&T (2) 
____3. Ultrafine forceps- 545 (1) 
____4. Curved iris scissors (1) 
____5. Microdissection scissors (1) 
____6. Gauze sponges- 2x2 and 4x4 
____7. Cotton swabs 
____8. 6.0 silk suture (2 x 1-inch pieces) 
____9. 7.0 prolene suture 
____10. Needle holder (1) 
 
Obtain in surgery suite 
____11. Depilatory cream- Veet 
____12. Non-sterile cotton swabs 
____13. Non-sterile gauze sponges (2x2 and 4x4) 
____14. Chlorhexidene diacetate (Nolvasan) 
____15. 1-mL insulin syringes (2) 
____16. Buprenorphine analgesic (0.03 mg·ml-1) 
____17. Ear punch 
____18. Veterinary ointment 
____19. Surgical tape 
____20. FST heat pad w/ rectal probe 
____21. Surgical scrubs 
____22. Sterile petri dish (1) 
____23. Sterile 5-mL syringe (1) 
____24. Sterile saline 
____25. Isolation mask and cap 
____26. Sterile gloves 
____27. Recovery bin and heat pad 
____28. 70% isopropyl alcohol (IPA) 
 
Animal preparation 
____29. Spray surgery area with Nolvasan. 
____30. Place animal in induction chamber. 
____31. Open oxygen cylinder. Set flow high and 
isofluorane to 5%. 
____32. Once anesthetized, weigh animal and move 
to preparatory bench in a supine position. 
____33. Reduce isoflurane to 1-3% and flow to 0.5-
1.5 l·min-1. 
 
____34. Gently apply veterinary ointment to eyes 
using a cotton swab. 
____35. Apply depilatory cream to hindlimb with a 
cotton swab and let sit for 1-3 minutes. 
____36. Spray a 2x2 gauze sponge with Nolvasan 
and wipe hindlimb clean of cream and hair. 
____37. Flip animal over and apply ear punch. 
____38. Administer pre-op buprenorphine dose 
(0.075 mg·kg-1) by subcutaneous injection. 
____39. Cover heat pad with a 4x4 gauze sponge and 
transfer animal to surgery stage. 
____40. Apply lubricant to rectal probe and insert. 
Set thermo-controller to 35°C. 
____41. Change into surgical scrubs and wash 
hands/forearms. 
____42. Open sterile instrument tray and sterile pack. 
____43. Obtain sterile petri dish in sterile field and 
fill with sterile saline, using a 5-mL syringe. 
____44. Put on mask, cap, and sterile gloves. 
 
Surgery 
____45. Make a small incision on the middle, medial 
aspect of the left hindlimb, directly over the 
neurovascular bundle. 
____46. Extend incision to the abdominal wall  
____47. Blunt dissect subcutaneous connective tissue 
to maximize surgical exposure. 
____48. Blunt dissect and retract epigastric fat pad to 
expose ligation site, proximal to the 
popliteal artery and distal to the epigastric. 
____49. Blunt dissect connective tissue over bundle 
and separate nerve from the artery-vein pair. 
____50. Use ultrafine forceps to separate the artery 
from the vein. 
____51. Tie off the femoral artery with silk suture. 
____52. Use 7-0 prolene suture to close the incision 
with spiral sutures. 
____53. Make a small incision in the middle medial 
aspect of the left hindlimb. 
____54. Extend incision to the abdominal wall  
____55. Blunt dissect subcutaneous connective tissue 
to maximize surgical exposure. 
____56. Use 7-0 prolene suture to close the incision 
with spiral sutures. 
 
Post-Surgical  
____57. Administer post-op buprenorphine dose 
(0.075 mg·kg-1) by subcutaneous injection. 
____58. Microwave recovery heat pad for ~1-2 min.  
____59. Transfer animal to recovery bin. 
____60. Turn off isoflurane, flow, and close oxygen. 
____61. Wipe down surgical area with IPA and wash 
all instruments. 
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 Superfusion -Vascular Reactivity  
Purpose: To specifically modulate different 
pathways affecting vasoreactivity at increasing 
doses on the sham and ligated side to evaluate how 
arteriogenesis affects the underlining pathway 
 
Safety Concerns: 
• Check SDS and SOP for all pharmacological 
agents.  
• Be careful of residual heat from syringe 
heater. 
• Be careful of sharp edges instruments 
• Dispose of mouse in carcass container 
• Dispose of all waste in appropriate labeled 
waste container 
 
Materials: 
1. Standard pattern forceps (1) 
2. Fine forceps- S&T (2) 
3. Curved iris scissors (1) 
4. Depilatory cream – Veet 
5. Cotton swabs 
6. Gauze sponges (2X2 and 4X4) 
7. Chlorhexidene diacetate (Nolvasan) 
8. 70% isopropyl alcohol (IPA) 
9. Jelly 
10. Surgical tape 
11. FST heat pad w/rectal probe 
12. Petri dish w/ PBS 
13. Syringe Heater 
14. 10ml Graduated cylinder 
15. Hot plate 
16. 5% CO2 – 95% N2 with tubing 
17. Supefusion tubing 
18. Vacuum pump evacuation flask 
19. Physiological salt solution (PSS) (stock solution 20X 
in 4oC 
20. Sodium bicarbonate  
21. Vasodilator/vasoconstrictor 
22. Trans-illuminator 
23. Intravial microscope – Qcapture Pro 
24. Kim wipes 
25. Plastic wrap 
26. Petri dish 
27. 500ml beaker 
28. 60ml syringe (x2)  
29. 18 ohmic water 
30. 1 L volumetric flask 
31. Instrument stand 
32. Sodium nitroprusside (SNP) 
33. 1M Hydrochloric acid (HCl) 
 
Instrument Preparation 
34. Dilute sodium bicarbonate (20x) and PSS (20x) in 18 
MW water using 1L volumetric flask 
35. Pour ~300 ml in 500ml beaker and place on hot plate. 
Turn hot plate on to ~85C 
36. Place syringe heater on instrument stand and insert 2 
60ml syringes in outside slots 
37. Put stopcocks on 60ml syringes and connect tubing 
38. Pour ~50ml in each 60ml syringe and turn syringe 
heater on 
39. Put aliquoted reagent in middle slot of the syringe 
heater 
 
Animal Preparation 
40. Prepare animal for surgical exposure 
 
Surgical Exposure 
41. Bubble 5% CO2 – 95% N2 in 60 ml syringes and cover 
with plastic wrap 
42. Make a small incision on the middle, medial aspect of 
the thigh 
43. Extend the incision up the abdominal wall 
44. Cut away the skin above the gracilis muscles and the 
collateral circuit to expose the region from the 
profundal to the saphenous 
45. Very gently, blunt dissect and remove the connective 
tissue overlying the gracilis muscle 
46. Move surgical stage underneath the BXFM 
47. Position the trans-illuminator LED probe underneath 
the limb, below the gracilis 
48. Open QCapture Pro and position the intravital 
microscope above the collateral arteriole in the gracilis 
anterior 
 
Superfusion 
49. Support superfusion tubing with instrument stand and 
place over exposed gracilis muscles 
50. Place a kim wipe that has been torn in half on top of 
plastic wrap and roll it to make a wick. Place on top of 
thigh (make sure not to touch muscle) and the other 
end in a petri dish 
51. Open stopcocks to syringe heater and check pH (7.2-
7.4), flow rate (~2 ml min-1), and temperature (~35oC) 
of PSS and keep running. Continuously check 
throughout remainder of procedure 
52. Allow muscle to stabilize (~30 minutes) 
53. Use the vacuum pump to remove PSS from petri dish 
as needed.  
54. Add PSS to 60ml syringe as needed (roughly every 10 
minutes) during the 30 minute rest period 
55. Acquire resting diameter of collateral 
56. Top of 60ml syringe with PSS 
57. Place first dosage of reagent in appropriate 60ml 
syringe (left or right depending on sham or ligated 
side) 
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 Superfusion -Vascular Reactivity  
58. Capture images at 5 minutes (or longer if need be (look 
in literature or do pilot study)) 
59. Refill 60ml syringe 
60. Place next dose of reagent in appropriate slot for 60ml 
syringe 
61. Repeat steps 66-68 until all concentrations have been 
used 
62.  Quickly flush 60ml syringe with PSS to remove 
residual pharmacological agents 
63. Repeat on sham side 
64. Repeat with additional pharmacological agents 
65. Close stopclock and stop PSS flow 
66. Put .6 ml 10-3 M SNP into 60ml syringe and superfuse 
over exposed gracilis collateral. Image 
 
Post Experiment 
67. If perfuse fixing, fix mouse and remove gracilis 
anterior  
68. Perform Cervical dislocation to euthanize animal and 
dispose of in bag and place in carcass box in -20C 
freezer 
69. Turn off isofluorane, flow, and close oxygen 
70. Turn off hot plate 
71. Flush superfusion line with 1M HCl and rinse with 
distilled water 
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Date ______________ Perfusion Fixation Initials ___________ 
 
Mouse Information 
DOB: ___________________ 
Sex: ____________________  
Tag: ____________________ 
Genotype/strain: __________ 
Cage: ___________________ 
Weight(g): _________________ 
 
Materials 
Non-Sterilize Dissection Instruments 
____1. Forceps (1) 
____2. Fine forceps (2) 
____3. Bone scissors (1) 
____4. Curved Iris scissors (1) 
____5. Microdissection scissors (1) 
____6. Vascular clamp (1) 
____7. Castroviejos  
 
Obtained in surgery suite 
____8. Tape 
____9. 20 mL syringes (2) 
____10. 5 mL syringe (1) 
____11. Syringe pump 
____12. Petri-dish 
____13. Bench cover 
____14. Depilatory cream 
____15. Clippers 
____16. Veterinary ointment  
____17. Heating pad 
____18. Catheter 
____19. Non-sterile saline 
____20. Cotton swabs 
____21. Gauze sponges  
____22. Saran wrap 
 
Vasodilator Cocktail Preparation 
____23. Turn on water bath to 37ºC 
____24. 400 µL heparin  
____25. 1mL SNP(orange) 
____26. 600µL Adenosine(clear) 
____27. 38mL PBS solution 
____28. 5 mL 4% Paraformaldehyde (PFA) 
____29. Thaw SNP, Adenosine and PFA 
____30. Add heparin, SNP, Adenosine, and PBS 
solution together in a 50mL conical 
____31. Place vasodilator cocktail in water bath 
 
Procedure Preparation 
____32. Obtain saline filled petri-dish, cotton 
swab, and instruments  
 
Fixation 
____33. Remove hair on back by shaving & 
depilation  
____34. Tape animal in supine position to 4X4 
gauze sponge over heating pad 
____35. Expose muscles of interest and blunt 
dissect to aid in removal post-fixation, 
then cover with saran wrap 
____36. Fill 20mL syringe with 20 mL warm 
Vaso D, load into syringe pump and 
attach catheter 
____37. Flow liquid through the catheter to the 
tip to prevent air from being injected 
into circulatory system 
____38. Lift skin from muscle in abdominal 
region and cut a window over the 
sternum 
____39. Lift sternum and cut connective tissue 
under 
____40. Use bone scissors in hole to quickly cut 
through the ribs to the armpit on both 
sides  
____41. Clamp sternum with castroviejos and 
reflect towards mouse’s head 
____42. Cut diaphragm with curved iris scissors 
to open chest cavity  
____43. Cut away excess tissue around the heart 
____44. Make a small incision in the apex of the 
heart 
____45. Insert catheter and clamp with vascular 
clamp and cut right atrium 
____46. Inject Vaso D solution into animal 
approximately 2x 20mL (5mL/min), 
soaking up excess blood and fluids with 
gauze sponges  
____47. Inject 5 mL PFA (4 mL/min) 
____48. Dissect out muscles of interest using fine 
forceps and microdissection scissors  
____49. Turn off water bath, cover scope, turn 
off oxygen, turn off isofluorane, and 
clean instruments 
 
Notes 
 _________________________________________ 
 _________________________________________ 
 _________________________________________ 
 _________________________________________ 
 _________________________________________ 
 _________________________________________ 
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Date: ________ Whole Mount Immunofluorescent  Initials: _____ 
Purpose: To stain gracilis anterior muscles with a-smooth muscle actin and tyrosine 
hydroxylase. This will provide insight into how innervation is impacted by arteriogenesis.  
 
 
Materials:  
• 24 well plate 
• Phosphate Buffer Saline (PBS) 
• TritonX-100 10% (Triton) 
• Bovine Serum Albumin (BSA) 
• Anti-Actin a-smooth muscle – Cy-3 
antibody 1:300 (a-SMA) (C6198) 
• Standard pattern forceps 
• Glycerol 
 
 
• Anti-tyrosine hydroxylase antibody 
1:1000 (THir) (AB152) 
• Alexa 488 goat-anti rabbit 1:100 
(secondary) (A11008) 
• Glass cover slips 
• Depression slides 
• Aluminum foil 
• Cover slips 
• Nail polish 
 
 
Methods: 
• Place muscle in 2 ml centrifuge tubes 
with 500 µL of 2% Triton in 1X PBS 
and incubate at room temperature 
(RT) for 2 hours shaking 
incrementally 
• Place muscle in 600 µL 
microcentrifuge tubes with 300 µL of 
0.1% Triton, 2% BSA, 1:300 a-SMA, 
1:1000 THir in 1X PBS 
• Wrap 24 well plate in aluminum foil 
and incubate at 4°C for 96 hours. 
Cover everything in foil from here on 
out 
• Wash in PBS 3X for 10 minutes at RT 
 
 
 
 
• Incubate with 1:100 secondary for 24 
hours at RT  
• Wash in 0.1% Triton in PBS 3X for 
10 minutes at RT 
• Wash in PBS for 30 min at RT 
• Place muscle on depression slide. 
Using transfer pipet drip 1 to 2 drops 
of 50/50 glycerol PBS on muscle 
• Place cover slide and paint edges with 
nail polish 
• Store in 4°C and wait at least 1 day 
before imaging 
 
Notes: 
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